GERMANTOWN, Md., Aug. 6, 2024
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced
it has commenced a $30.0 million
underwritten public offering of its common stock. In addition,
Precigen intends to grant the underwriters a 30-day option to
purchase up to an additional $4.5
million of common stock. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the size or terms
of the offering. All of the shares in the proposed offering are to
be sold by Precigen.
Stifel is acting as the sole book-running manager for the
offering.
The public offering will be made pursuant to a shelf
registration statement on Form S-3 that was previously filed with
the Securities and Exchange Commission (SEC) and became effective
on January 17, 2024. A preliminary
prospectus supplement and accompanying base prospectus relating to
and describing the terms of the offering will be filed with the SEC
and will be on the SEC's website at www.sec.gov. Copies of the
preliminary prospectus supplement and base prospectus relating to
this offering may be obtained, when available, from Stifel,
Nicolaus & Company, Incorporated, Attention: Prospectus
Department, One Montgomery Street,
Suite 3700, San Francisco, CA
94104, by telephone at +1 (415) 364-2720 or by email at
syndprospectus@stifel.com. The final terms of the offering will be
disclosed in a final prospectus supplement to be filed with the
SEC.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these shares in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Precigen
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies are designed
to enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated therapies toward clinical proof-of-concept
and commercialization.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon Precigen's current expectations and projections
about future events, including the proposed public offering and the
size or terms of such offering. Various factors may cause
differences between Precigen's expectations and actual results.
These risks and uncertainties include, without limitation, risks
and uncertainties related to market conditions and satisfaction of
customary closing conditions related to the proposed public
offering, as well as that we have broad discretion in the use of
proceeds. There can be no assurance that Precigen will be able to
complete the proposed public offering on the anticipated terms, or
at all. For further information on potential risks and
uncertainties, and other important factors, any of which could
cause Precigen's actual results to differ from those contained in
the forward-looking statements, see the section entitled "Risk
Factors" in Precigen's most recent Annual Report on Form 10-K and
subsequent reports filed with the Securities and Exchange
Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-announces-proposed-30-million-public-offering-of-common-stock-302215911.html
SOURCE Precigen, Inc.